<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=10498&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="415205" class="table-">
                
                <td>June 23, 2022, 2 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;Interferon-alpha;Interferon-gamma;Interferons;Injections; Subcutaneous;Chloroquine;Azithromycin;HeberFERON\rKaletra\rRocephin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;Interferon-alpha;Interferon-gamma;Interferons;Injections; Subcutaneous;Chloroquine;Azithromycin;HeberFERON\rKaletra\rRocephin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 668, &quot;treatment_name&quot;: &quot;Interferon alpha gamma&quot;, &quot;treatment_type&quot;: &quot;Interferons&quot;, &quot;pharmacological_treatment&quot;: &quot;Pharmacological treatment&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 667, &quot;treatment_name&quot;: &quot;Interferon alpha2b&quot;, &quot;treatment_type&quot;: &quot;Interferons&quot;, &quot;pharmacological_treatment&quot;: &quot;Pharmacological treatment&quot;}, {&quot;arm_notes&quot;: &quot;no third arm&quot;, &quot;treatment_id&quot;: 667, &quot;treatment_name&quot;: &quot;Interferon alpha2b&quot;, &quot;treatment_type&quot;: &quot;Interferons&quot;, &quot;pharmacological_treatment&quot;: &quot;Pharmacological treatment&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="414295" class="table-">
                
                <td>June 17, 2022, 12:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Interferon alpha-2;Interferon-alpha;Interferon-gamma;Interferons;Injections; Subcutaneous;Chloroquine;Azithromycin;HeberFERON\rKaletra\rRocephin\r;Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 668, &quot;treatment_name&quot;: &quot;Interferon alpha gamma&quot;, &quot;treatment_type&quot;: &quot;Interferons&quot;, &quot;pharmacological_treatment&quot;: &quot;Pharmacological treatment&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 667, &quot;treatment_name&quot;: &quot;Interferon alpha2b&quot;, &quot;treatment_type&quot;: &quot;Interferons&quot;, &quot;pharmacological_treatment&quot;: &quot;Pharmacological treatment&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="251740" class="table-">
                
                <td>May 27, 2021, 12:45 a.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;Interferon-alpha;Interferon-gamma;Interferons;Injections; Subcutaneous;Chloroquine;Azithromycin;HeberFERONKaletraRocephin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;Interferon-alpha;Interferon-gamma;Interferons;Injections; Subcutaneous;Chloroquine;Azithromycin;HeberFERONKaletraRocephin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 668, &quot;treatment_name&quot;: &quot;Interferon alpha gamma&quot;, &quot;treatment_type&quot;: &quot;Interferons&quot;, &quot;pharmacological_treatment&quot;: &quot;Pharmacological treatment&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 667, &quot;treatment_name&quot;: &quot;Interferon alpha2b&quot;, &quot;treatment_type&quot;: &quot;Interferons&quot;, &quot;pharmacological_treatment&quot;: &quot;Pharmacological treatment&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="223711" class="table-">
                
                <td>Oct. 26, 2020, 8:29 a.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks. Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks. All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;HeberFERON Kaletra Rocephin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks. All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;HeberFERON Kaletra Rocephin&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
June 23, 2022, 2 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;Interferon-alpha;Interferon-gamma;Interferons;Injections; Subcutaneous;Chloroquine;Azithromycin;HeberFERON\rKaletra\rRocephin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;Interferon-alpha;Interferon-gamma;Interferons;Injections; Subcutaneous;Chloroquine;Azithromycin;HeberFERON\rKaletra\rRocephin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 668, "treatment_name": "Interferon alpha gamma", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 667, "treatment_name": "Interferon alpha2b", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "no third arm", "treatment_id": 667, "treatment_name": "Interferon alpha2b", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}]
June 17, 2022, 12:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Interferon alpha-2;Interferon-alpha;Interferon-gamma;Interferons;Injections; Subcutaneous;Chloroquine;Azithromycin;HeberFERON\rKaletra\rRocephin\r;Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 668, "treatment_name": "Interferon alpha gamma", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 667, "treatment_name": "Interferon alpha2b", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}]
May 27, 2021, 12:45 a.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;Interferon-alpha;Interferon-gamma;Interferons;Injections; Subcutaneous;Chloroquine;Azithromycin;HeberFERONKaletraRocephin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks.All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;Interferon-alpha;Interferon-gamma;Interferons;Injections; Subcutaneous;Chloroquine;Azithromycin;HeberFERONKaletraRocephin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 668, "treatment_name": "Interferon alpha gamma", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 667, "treatment_name": "Interferon alpha2b", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}]
Oct. 26, 2020, 8:29 a.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks. Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks. All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;HeberFERON Kaletra Rocephin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group A: HeberFERON (Recombinant Interferon Alpha Gamma; 3.5 MUI); subcutaneously; twice a week for three consecutive weeks.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b; 3.0 MUI); subcutaneously; three times per week for three consecutive weeks. All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra; chloroquine; azithromycin or rocefin; depending on the magnitude of respiratory symptoms.;Interferon alpha-2;HeberFERON Kaletra Rocephin", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]